Canon Medical Systems announced that the U.S. Food & Drug Administration (FDA) has cleared its Compressed SPEEDER technology for use in the company’s Vantage Orian 1.5T MRI system.
Canon Medical Systems announced that the U.S. Food & Drug Administration (FDA) has cleared its Compressed SPEEDER technology for use in the company’s Vantage Orian 1.5T MRI system.
The technology, which is also available on the Vantage Galan 3T MRI system, can help reduce overall MRI scan times by reconstructing full resolution images from under-sampled data and avoiding unfolding error artifacts. In addition, it can help capture higher resolution images in 2D Fast Spin Echo acquisitions.
Reduced scan time not only presents an advantage for patients who find it difficult to remain still during long scans, but it also allows for additional time for disinfection of MRI systems and imaging suites between patients as practices begin to return to more normal patient volumes.
Faced with new, stringent cleaning protocols, more complex patient appointment management and other changes to workflow, the Compressed SPEEDER technology may help ease some post-pandemic growing pains for radiology departments and practices as many work to adjust to the “new normal.”
Canon’s new technology is included in an updated version of the M-Power software available for the Vantage Orian 1.5T. The software comes standard with Windows 10 and cybersecurity functionality, including continuous updates from Microsoft and whitelisting functions which allow for access only to authorized applications and processes.
“In MR imaging, shortening scan times is vastly important for both the patient and physician,” said Jonathan Furuyama, managing director, MR Business Unit, Canon Medical Systems USA, Inc., in a statement. “With the help of Compressed SPEEDER along with Windows 10 on the Vantage Orian 1.5T MR system, healthcare providers can offer a quick, comfortable and safe experience for their patients.”
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.